• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干燥综合征生物制剂治疗中的免疫监测:监测什么、何处监测、何时监测以及如何监测。

Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How.

作者信息

van Beers Joyce J B C, Damoiseaux Jan G M C

机构信息

Central Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology and Clinical Chemistry, 6202 AZ Maastricht, The Netherlands.

Central Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology, 6202 AZ Maastricht, The Netherlands.

出版信息

Biomolecules. 2021 Jan 16;11(1):116. doi: 10.3390/biom11010116.

DOI:10.3390/biom11010116
PMID:33467204
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7830440/
Abstract

Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in Sjögren's syndrome, as well as different approaches to monitoring the immune system, are discussed.

摘要

多年来,多种治疗性抗体已成功引入自身免疫病临床,还有更多正在研发中。这些治疗方法大多针对致病性循环分子或细胞结合分子。针对前者靶点会导致可溶性因子中和,而与后者靶点结合则会抑制细胞功能或诱导选择性细胞死亡。如果这种靶向分子或细胞是免疫系统的一部分,这种疗法会引发免疫缺陷状态,可能导致感染。因此,需要进行免疫监测以预防免疫治疗的此类不良副作用。本文讨论了干燥综合征中使用的不同免疫疗法以及监测免疫系统的不同方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/9d1857645d87/biomolecules-11-00116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/96ce75be9198/biomolecules-11-00116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/f7123da797d2/biomolecules-11-00116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/9d1857645d87/biomolecules-11-00116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/96ce75be9198/biomolecules-11-00116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/f7123da797d2/biomolecules-11-00116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/7830440/9d1857645d87/biomolecules-11-00116-g003.jpg

相似文献

1
Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How.干燥综合征生物制剂治疗中的免疫监测:监测什么、何处监测、何时监测以及如何监测。
Biomolecules. 2021 Jan 16;11(1):116. doi: 10.3390/biom11010116.
2
Limited efficacy of targeted treatments in Sjögren's syndrome: why?靶向治疗在干燥综合征中的疗效有限:原因何在?
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):27-28. Epub 2018 Jun 21.
3
Biologics in Sjögren's syndrome.干燥综合征中的生物制剂。
Pharmacol Res. 2019 Sep;147:104389. doi: 10.1016/j.phrs.2019.104389. Epub 2019 Aug 12.
4
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.生物制剂治疗干燥综合征、系统性红斑狼疮和狼疮性肾炎。
Curr Opin Rheumatol. 2020 Nov;32(6):609-616. doi: 10.1097/BOR.0000000000000754.
5
[Use of physalaemin in the treatment of Sjogren's disease].[使用 Physalaemin 治疗干燥综合征]
Ann Ottalmol Clin Ocul. 1969 Dec;95(12):945-60.
6
Treatment of Sjögren's syndrome: current therapy and future directions.干燥综合征的治疗:当前疗法和未来方向。
Rheumatology (Oxford). 2021 May 14;60(5):2066-2074. doi: 10.1093/rheumatology/kez142.
7
[Indications and options of new immune modulatory therapies for Sjögren's syndrome].[干燥综合征新免疫调节疗法的适应证及选择]
Z Rheumatol. 2007 Dec;66(8):679-85. doi: 10.1007/s00393-007-0231-z.
8
Sjogren's Disease.干燥综合征
Rheum Dis Clin North Am. 2016 Aug;42(3):xi-xii. doi: 10.1016/j.rdc.2016.06.002.
9
Present and future of biologic drugs in primary Sjögren's syndrome.原发性干燥综合征中生物药物的现状与未来。
Expert Opin Biol Ther. 2017 Jan;17(1):63-75. doi: 10.1080/14712598.2017.1235698. Epub 2016 Sep 20.
10
Sjögren Syndrome in the Twenty-First Century.21世纪的干燥综合征
Rheum Dis Clin North Am. 2016 Aug;42(3):xiii-xiv. doi: 10.1016/j.rdc.2016.06.001.

引用本文的文献

1
Retrospective analysis of the efficacy of total glycosides of paeony capsules combined with hydroxychloroquine in patients with primary Sjogren's syndrome.白芍总苷胶囊联合羟氯喹治疗原发性干燥综合征患者疗效的回顾性分析
Pak J Med Sci. 2025 May;41(5):1429-1434. doi: 10.12669/pjms.41.5.11102.
2
Exploring risk factors for autoimmune diseases complicated by non-hodgkin lymphoma through regulatory T cell immune-related traits: a Mendelian randomization study.通过调节性 T 细胞免疫相关特征探讨自身免疫性疾病并发非霍奇金淋巴瘤的危险因素:一项孟德尔随机研究。
Front Immunol. 2024 May 28;15:1374938. doi: 10.3389/fimmu.2024.1374938. eCollection 2024.
3

本文引用的文献

1
Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).阿巴西普治疗早期活动性原发性干燥综合征患者:一项单中心、随机、双盲、安慰剂对照的3期试验(ASAP-III研究)。
Lancet Rheumatol. 2020 Mar;2(3):e153-e163. doi: 10.1016/S2665-9913(19)30160-2. Epub 2020 Jan 31.
2
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.原发性干燥综合征患者抗CD40抗体伊斯卡利单抗的评估:一项多中心、随机、双盲、安慰剂对照的概念验证研究。
Lancet Rheumatol. 2020 Mar;2(3):e142-e152. doi: 10.1016/S2665-9913(19)30135-3. Epub 2020 Jan 23.
3
Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren's syndrome.
基于网络药理学的策略研究青蒿素治疗原发性干燥综合征的作用机制。
BMC Immunol. 2024 Feb 12;25(1):16. doi: 10.1186/s12865-024-00605-3.
4
Detection of CTLA-4 level and humeral immune response after the second dose of COVID-19 vaccine in certain Iraqi provinces participants.检测某些伊拉克省份参与者在接种第二剂 COVID-19 疫苗后 CTLA-4 水平和肱骨免疫反应。
PLoS One. 2024 Jan 5;19(1):e0296521. doi: 10.1371/journal.pone.0296521. eCollection 2024.
Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.依那西普治疗原发性干燥综合征的疗效和安全性:一项随机、安慰剂对照临床试验。
Scand J Rheumatol. 2021 Mar;50(2):143-152. doi: 10.1080/03009742.2020.1809701. Epub 2020 Oct 29.
4
Ten years of the ESSDAI: is it fit for purpose?ESSDAI 十年:是否符合目的?
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):283-290. Epub 2020 Oct 23.
5
Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes.原发性干燥综合征的发病机制超出 B 淋巴细胞。
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):315-323. Epub 2020 Oct 23.
6
Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers.阻断原发性干燥综合征中的 T 细胞共刺激:原理、临床疗效以及外周和唾液腺生物标志物的调节。
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):222-227. Epub 2020 Oct 23.
7
One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren's syndrome.2020 年回顾:原发性干燥综合征的合并症、诊断和治疗。
Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):10-22. Epub 2020 Sep 16.
8
The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.依那西普治疗原发性干燥综合征患者的疗效和作用机制。
Int Ophthalmol. 2020 Nov;40(11):3059-3065. doi: 10.1007/s10792-020-01490-6. Epub 2020 Jul 1.
9
The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders.ISCCA 用于监测自身免疫性疾病中抗 CD20 治疗的流程方案。
Cytometry B Clin Cytom. 2021 Mar;100(2):194-205. doi: 10.1002/cyto.b.21930. Epub 2020 Jun 29.
10
T follicular helper cell subsets: a potential key player in autoimmunity.滤泡辅助性 T 细胞亚群:自身免疫中的潜在关键因素。
Immunol Med. 2021 Mar;44(1):1-9. doi: 10.1080/25785826.2020.1776079. Epub 2020 Jun 17.